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 Abstract
Moderate and severe forms of allergic diseases such as atopic dermatitis and asthma are a challenge for clinicians. In these conditions, 
which severely affect the quality of life of the patient and frequently have associated allergic comorbidities, the therapeutic options are 
often very limited. Treatment with systemic corticosteroids and immunosuppressants has adverse effects in the long term, and a significant 
proportion of patients remain refractory to therapy. In this context, the emerging biological drugs constitute a truly innovative therapeutic 
approach. A leading example is dupilumab, a monoclonal antibody targeting the α chain of the interleukin (IL)-4 receptor. Dupilumab 
inhibits the biological effects of the cytokines IL-4 and IL-13, which are key drivers in the TH2 response. The efficacy and safety profile 
of dupilumab in the treatment of allergic diseases has been tested for more than 10 years in a variety of large clinical trials in atopic 
dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, and eosinophilic esophagitis. In 2017, the United States Food and Drug 
Administration and the European Medicines Agency approved the use of dupilumab for the treatment of adult patients with moderate-
to-severe atopic dermatitis whose disease is not adequately controlled with prescribed topical treatment. The results of phase III clinical 
studies of dupilumab in patients with persistent, uncontrolled asthma have been highly promising. The safety and tolerability profile of 
dupilumab has proven to be very favorable in long-term clinical trials. In this review, we focus on the mechanism of action of dupilumab, 
its development, and its impact on daily clinical practice in allergic diseases.
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 Resumen
Las formas clínicas moderadas y graves de enfermedades alérgicas comunes como la dermatitis atópica o el asma constituyen un reto para 
los clínicos. En estos casos, que afectan intensamente la calidad de vida del paciente y con frecuencia conllevan otras enfermedades alérgicas 
asociadas, las opciones terapéuticas son a menudo muy limitadas. El tratamiento con corticosteroides sistémicos o inmunosupresores tiene 
efectos adversos a largo plazo y una proporción significativa de pacientes se muestra refractaria a la terapia. En este contexto, los nuevos 
fármacos biológicos, dirigidos a la base inmunológica de la enfermedad, ofrecen un enfoque terapéutico verdaderamente innovador. Un 
ejemplo destacado de estos fármacos es dupilumab, un anticuerpo monoclonal dirigido contra la cadena alfa del receptor de la interleucina 
(IL)-4. Dupilumab inhibe los efectos biológicos de las citoquinas IL-4 e IL-13, unos de los principales efectores de la respuesta Th2. La 
efectividad y seguridad de dupilumab en el tratamiento de enfermedades alérgicas se han probado durante más de diez años en una 
variedad de grandes ensayos clínicos en dermatitis atópica, asma, rinosinusitis crónica con poliposis nasal y esofagitis eosinofílica. La FDA 
y la EMA aprobaron en 2017 el uso de dupilumab en el tratamiento de pacientes adultos con dermatitis atópica moderada o grave que 
no se controla adecuadamente con tratamiento tópico. Los estudios clínicos de Fase 3 de dupilumab en pacientes con asma persistente 
no controlada también han sido muy prometedores. En los ensayos clínicos a largo plazo la seguridad y tolerabilidad de dupilumab ha 
demostrado ser muy elevada. En esta revisión nos hemos centrado en el mecanismo de acción de dupilumab, su desarrollo como fármaco 
y su impacto en la terapia de enfermedades alérgicas.
Palabras clave: Alergia. Dermatitis atópica. Asma. Medicamentos biológicos. Dupilumab.
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Introduction: Allergic Diseases
Allergic diseases are characterized by hypersensitivity to 
specific allergens, which generally leads to increased serum 
levels of IgE [1-3]. Predisposed individuals typically present 
1 or more of a spectrum of interconnected disorders, namely, 
atopic dermatitis (AD), allergic asthma, allergic rhinitis, food 
allergy, hymenoptera allergy, or eosinophilic esophagitis 
(EoE). Allergic diseases are notoriously heterogeneous 
and result from a complex interaction between genetic and 
environmental factors [4]. For reasons not fully understood, 
allergic diseases are increasing in prevalence worldwide. Thus, 
AD is one of the most common skin diseases, with prevalences 
of up to 25% in children and 2%-5% in adolescents [5]. The 
estimated worldwide prevalence of AD in adults, where the 
disease can often be severe, has been estimated at 1%-3% [6,7]. 
In Spain the prevalence of severe AD is 0.08% [8]. On the other 
hand, asthma affects 1%-18% of the population depending on 
the country, or about 300 million people worldwide [2]. The 
prevalence of allergic rhinitis varies widely by country, but it 
is estimated that 16% of adults in Europe could be affected [9]. 
Chronic rhinosinusitis affects 10.9% of people in Europe [10], 
and EoE is increasingly prevalent worldwide (currently 0.4% in 
developed countries) [11]. Finally, IgE-mediated food allergy 
could affect as many as 4%-7% of preschool children and has 
been increasing in frequency in both developed and developing 
countries in recent decades [12,13].
Allergic diseases often develop sequentially at different 
stages of life in the same individuals, possibly because of 
a shared genetic origin. For example, a recent study of 380 
adult AD patients showed that 40.3% had asthma, 51.3% had 
allergic rhinitis, 24.2% had allergic conjunctivitis, and 60.5% 
had other allergic conditions [14]. In addition, AD in early 
childhood is strongly associated with asthma later in life [15] 
and can have a huge impact on the quality of life (QOL) of 
affected individuals. The secondary effects of the illness can 
result in profound emotional, psychological, economic, and 
social burdens for patients and their families [16]. In the 
case of asthma, although patients with severe forms of the 
disease represent a minority of the total asthma population, 
they frequently experience comorbidities and account for an 
important part of asthma-associated health care costs [17].
Clinically and mechanistically, allergic diseases are 
characterized by systemic inflammation and type-2 helper 
T-cell (TH2) activation, which in turn is characterized by the 
production of interleukin (IL) 4, IL-5, IL-9, and IL-13. For 
example, activation of TH2 in the airways leading to production 
of eosinophilia or IgE occurs in about 50% of asthmatics [18]. 
For this reason, recently developed biological therapies for 
allergic diseases have mainly targeted either the final product, 
IgE [19], or the key proximal type-2 cytokines, namely, IL-4, 
IL-5, and IL-13 [20,21].
Dupilumab is a fully human monoclonal antibody directed 
against IL-4Rα, which inhibits IL-4/IL-13 signaling and thus 
downregulates type-2 immunity. The United States Food and 
Drug Administration (FDA) approved dupilumab (Regeneron 
Pharmaceuticals) in March 2017 for “the treatment of adult 
patients with moderate-to-severe atopic dermatitis whose 
disease is not adequately controlled with topical prescription 
therapies or when those therapies are not advisable” [22,23]. 
In October of the same year it was also approved by the 
European Medicines Agency (EMA) for “the treatment of 
moderate-to-severe atopic dermatitis in adult patients who 
are candidates for systemic therapy” [24]. In addition to AD, 
dupilumab has proven effective in the treatment of severe and 
persistent asthma and is being actively investigated for chronic 
rhinosinusitis with nasal polyposis and for EoE (see below).
In this review, we focus on dupilumab and its mechanism 
of action, the randomized clinical trials evaluating its efficacy 
and safety, and its therapeutic value in daily clinical practice 
for the treatment of AD, asthma, rhinitis, and EoE.
Allergic Diseases: Current Therapeutic 
Options
Topical corticosteroids are the main treatment of mild 
and moderate forms of atopic diseases [1,2]. In the case of 
AD, topical calcineurin inhibitors (eg, tacrolimus ointment 
and pimecrolimus cream) and topical phosphodiesterase-4 
inhibitors are also approved therapies. Moderate or recurrent 
forms of AD may require stronger topical corticosteroids 
or phototherapy, and treatment of severe forms of AD may 
require systemic corticosteroids and immunosuppressants 
such as cyclosporine A, azathioprine, mycophenolate mofetil, 
enteric-coated mycophenolate sodium, and methotrexate [25]. 
However, in the most severe cases, treatment options are 
quickly exhausted owing to significant adverse effects of 
topical corticosteroids and immunosuppressants in the long 
term, which often limit treatment [1]. Dupilumab is currently 
the only biological drug approved for the treatment of 
moderate-to-severe AD in adults [23,24]. Other biological 
drugs are in phase II clinical trials, namely lebrikizumab 
(anti-IL-13), tralokinumab (anti-IL-13), nemolizumab (anti-
IL-31), and tezepelumab (anti-thymic stromal lymphopoietin), 
although further studies will be required to evaluate their 
effectiveness (reviewed in [26]).
Asthma is usually treated with inhaled or systemic 
corticosteroids, alone or in combination with other controller 
medications such as long-acting β2-adrenoreceptor agonists 
(LABAs) and cysteinyl-leukotriene receptor antagonists [2]. 
Despite the widely available effective therapies for the treatment 
of asthma, many asthma cases remain uncontrolled [27]. Severe, 
uncontrolled asthma can lead to corticosteroid dependence, 
with systemic exposure to these agents potentially leading to 
serious short- and long-term adverse effects, including weight 
gain, diabetes, osteoporosis, glaucoma, anxiety, depression, 
cardiovascular disease, and immunosuppression. Biological 
therapies approved for asthma include omalizumab (anti-
IgE), mepolizumab (anti–IL-5), reslizumab (anti–IL-5), and 
benralizumab (anti-IL-5Rα) [17]. Dupilumab successfully 
completed 2 large phase III clinical trials in 2017 (see 
below) [28-33]. 
Chronic rhinosinusitis is also a complex disease consisting 
of several variants with specific pathophysiologies [34], and 
treatment options are also often limited. Current treatments 
include topical corticosteroids and nasal saline irrigations [35], 
mometasone implants, and sinus surgery [3]. The biological 
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treatments omalizumab (anti-IgE) in the case of comorbid 
asthma and mepolizumab (anti-IL-5) have been successfully 
tested. As described below, dupilumab demonstrated efficacy in 
a phase II clinical trial, and phase 3 clinical trials are currently 
underway and expected to conclude in 2018.
No specific medications are currently approved by the 
FDA for treatment of EoE. Standard treatments include proton 
pump inhibitors, oral corticosteroids, dietary therapy, and 
dilation [36,37], usually with the objective of interrupting 
disease progression towards fibrosis. Phase II studies of 
dupilumab for the treatment of EoE have been completed, 
and phase III studies are ongoing (see below). Since EoE 
affects fewer than 200 000 people in the US, dupilumab has 
received orphan status from the FDA for the treatment of this 
disease [38].
Mechanism of Action of Dupilumab
Dupilumab is a recombinant human IgG4 antibody to 
the IL-4 receptor [39]. There are 2 types of IL-4 receptors: 
the type 1 receptor, which is composed of the IL-4 chain 
(IL-4Rα) and a γ chain (γC), and the type 2 receptor, which 
is composed of the IL-4Rα chain and the α1 chain of the 
IL-13 receptor (IL-13Rα1) (Figure). These receptors are 
present in the surface of a large number of cells involved in 
the pathophysiology of TH2 allergic responses, which include 
B lymphocytes, eosinophils, dendritic cells, monocytes/
macrophages, basophils, keratinocytes, bronchial epithelial 
cells, endothelial cells, fibroblasts, and airway smooth muscle 
cells [40]. The type 1 receptor can be activated by IL-4 and 
the type 2 receptor can be activated by both IL-4 and IL-13 
(Figure). Ligand binding to these receptors activates a signal 
transduction cascade that mainly leads to the modulation of 
expression of genes involved in IgE class switching, TH2 cell 
differentiation, and M2 macrophage polarization [21,39]. 
IL-4 has been shown to stimulate IgE production from 
B cells, and expression of IL-13 correlates with disease severity 
and flares [39]. In asthma, IL-4 plays a major role in TH2 cell 
proliferation, cytokine production, and IgE synthesis, and 
IL-13 has a major role in the pathological features of disease 
(mucus production, airway hyperresponsiveness, and collagen 
deposition) [21]. 
In AD, the cytokines IL-4 and IL-13 modulate the epidermal 
barrier [41] and inhibit antimicrobial peptide production [42]. 
IL-13 mRNA levels correlate with disease severity in lesional 
skin [43], and this cytokine is a potent stimulator of dermal 
inflammation and remodeling [44,45]. However, much 
remains to be known about the signaling processes (receptor 
distribution, utilization, assembly, and affinity for IL-4 and 
IL-13) and the activated genes that ultimately lead to allergic 
inflammatory states. 
Evidence from basic research and a very large body of 
evidence from clinical trials supports the model by which 
dupilumab binding to IL-4 receptors inhibits their activation by 
IL-4 and IL-13, thus blocking the signaling pathways involved 
in the development and progression of allergic responses. 
Dupilumab: Clinical Trials
Dupilumab for AD
The first trials on the safety and efficacy of dupilumab 
for the treatment of moderate-to-severe AD in adults were 
published in 2013. Large-scale phase II and III trials have 
been completed and confirm the benefits of the drug for adult 
AD cases (see below and Table 1); dupilumab was licensed by 
the FDA and the EMA in 2017 [23,24]. The main parameters 
for assessment of efficacy in clinical studies are generally 
the Investigator's Global Assessment (IGA), which measures 
overall severity of AD on a 6-point scale (0 = totally clear to 
5 = very severe)[46], and the Eczema Area and Severity Index 
(EASI), a scale for the assessment of severity and extent of 
AD and specifically designed for drug evaluation and clinical 
trials [47].
Phase I Studies
Phase I studies (NCT01259323, NCT01385657, 
NCT01015027) did not reveal safety concerns related to 
dupilumab (doses of up to 300 mg for 12 weeks) compared 
with placebo [48]. Inhibition of the TH2 immune pathway 
was demonstrated by significant suppression of thymus and 
activation regulated chemokine (TARC) and IgE in patients 
treated with dupilumab [48]. A pharmacokinetic study of the 
pooled participants of 6 phase I and II studies (N=197) revealed 
no differences in the rate of production of IL-4Rα between healthy 
volunteers and patients with AD or between the sexes [49].
Phase II Studies
A phase IIA trial carried out in European centers 
(NCT01548404) involving adults with moderate-to-severe AD 
despite treatment with topical corticosteroids and calcineurin 
inhibitors [50] showed that dupilumab monotherapy for 12 
weeks significantly improved the proportion of patients who 
Figure. Mechanism of action of dupilumab. Dupilumab is a fully human 
monoclonal antibody against IL-4Rα that inhibits IL-4/IL-13 signaling 
and targets type I (IL-4Rα/γC) and type II (IL-4Rα/ IL-13Rα1) receptors. 
Downstream signaling from these receptors, which is mainly mediated 
by phosphorylated STAT6, activates expression of numerous TH2-related 
genes, including those associated with IgE class switching.
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reached EASI-50 (85% of patients in the dupilumab group 
vs 35% of those in the placebo group, P<.001) and the IGA 
requirement (40% of patients in the dupilumab group vs 
7% in the placebo group, P<.001) and led to a decrease in 
pruritus scores (55.7% in the dupilumab group vs 15.1% in 
the placebo group, P<.001) [50]. In addition, the trial showed 
that biomarkers in serum and tissue indicated normalization 
of AD-affected skin compared with normal skin in patients 
treated with dupilumab [50] and that the QOL index for AD 
(QoLIAD) score improved significantly after 12 weeks of 
dupilumab treatment compared with placebo (mean percent 
changes of –64.0 [6.91] vs –11.1 [9.31], respectively) [51]. 
Furthermore, these QoLIAD scores significantly (P<.05) 
correlated with changes in efficacy outcomes, including 
EASI (r=0.4355), 5-dimensional pruritus (r=0.4937), pruritus 
numerical rating scale (r=0.4064), total SCORAD (r=0.5559), 
and SCORAD VAS scores for sleep (r=0.4681) and pruritus 
(r=0.5400) [51]. 
In another phase II trial (NCT01639040) in which 
dupilumab was administered to 31 adults diagnosed with 
chronic AD for at least 2 years in combination with background 
topical corticosteroids, 100% of patients in the dupilumab 
group achieved EASI-50 in 4 weeks, compared with 50% of 
the patients in the placebo group (P=0.002) [50].
Finally, Thaci et al [52] performed a large phase IIB trial 
(NCT01859988) of 380 adult patients from several countries 
with moderate-to-severe AD inadequately controlled by 
topical treatments (Table 1). The reductions in the EASI 
scores were very significantly favorable for all dupilumab 
treatments compared with placebo (P<.0001), with a reduction 
of up to 74% in the case of dupilumab 300 mg once a week 
compared with 18% for placebo [52]. In addition, this study 
made it possible to describe and quantify the large and 
multidimensional burden of disease associated with AD in 
the adult population [14]. Of note, treatment with dupilumab 
improved patient-reported outcomes (PROs) in sleep, mental 
health, and health-related QOL [14,52,53].
Phase III studies
SOLO-1 and SOLO-2 (NCT02277743 and NCT02277769, 
respectively) were large international, prospective, double-
blind, placebo-controlled trials of identical design with the 
goal of evaluating the efficacy and safety of dupilumab in 
monotherapy [54]. The participants (671 patients in SOLO-1 
and 708 in SOLO-2) were adults with a diagnosis of moderate-
to-severe AD inadequately controlled by topical treatment. 
Prohibited concomitant medications during the trials included 
topical or systemic corticosteroids and immunomodulating 
biologic agents. The primary outcome of the studies was the 
proportion of patients who had both an IGA score of 0 or 1 and 
a reduction of 2 or more points in that score from baseline at 
week 16. In SOLO-1/2, this endpoint was met by 38%/36% of 
patients taking dupilumab every other week and by 37%/36% 
of patients taking dupilumab weekly, compared with 10%/8% 
of patients taking placebo (P<.001 for all comparisons with 
placebo) [54]. Similarly, the percentages of patients reaching 
EASI-75 at week 16 were significantly higher for patients 
receiving dupilumab than for those receiving placebo 
(44%/52% vs 12%/15%, P<.0001). Reduction in pruritus 
and symptoms of anxiety or depression and improvement in 
QOL and other PROs were also significantly better in patients 
receiving the drug [54]. The disease burden of AD, as measured 
by impaired health-related QOL, was reduced significantly in 
the dupilumab groups relative to the placebo group and was 
clinically significant [55].
The LIBERTY AD CHRONOS study (NCT02260986) 
evaluated the long-term (1-year) efficacy and safety of 
dupilumab in combination with medium-potency topical 
corticosteroids (TCSs) in adults with moderate-to-severe AD 
(Table 1) [56-58]. The results at week 16 were maintained at 
1 year of treatment, showing a strong improvement in signs 
and symptoms of AD in the groups treated with dupilumab 
plus TCSs. IGA 0/1 was achieved by 39% of the patients 
who received dupilumab plus TCSs every week and 39% of 
those who received dupilumab every 2 weeks compared with 
12% of those who received placebo (P<.0001). Furthermore, 
EASI-75 was achieved by 64% of the patients who received 
dupilumab plus TCSs every week and 69% of those who 
received dupilumab every 2 weeks compared with 23% who 
received placebo (P<.0001) [56,57].
The LIBERTY AD CAFÉ (NCT02755649) trial was 
designed to evaluate dupilumab in combination with TCSs in 
adults with AD and an inadequate response or intolerance to 
cyclosporine A, or for whom cyclosporine A was medically 
inadvisable (Table 1) [59]. This study included data from 
318 patients who were randomized to 2 dupilumab regimens 
(once- or twice-weekly injections) and placebo, in all cases 
with concomitant TCSs. The main endpoint, EASI-75, was 
achieved by 59.1% and 62.6% of the patients in the treatment 
groups with weekly or biweekly dupilumab treatments, 
respectively, compared with 29.6% for placebo (P<.0001). 
Dupilumab in both regimens also significantly improved other 
clinical outcomes and AD symptoms, including pruritus, pain, 
sleep disturbance, symptoms of anxiety and depression, and 
QOL [59].
The LIBERTY AD CONTINUE (NCT02395133) trial 
was an extension study with 475 adults who had participated 
in SOLO-1 and SOLO-2. The results showed that patients 
who continued with the dosing regimen of SOLO 1 and 
SOLO 2 (300 mg every 2 weeks or every week) experienced 
an optimal effect in maintaining clinical response, while 
efficacy for other dose regimens diminished in a dose-
dependent manner [24].
Ongoing Trials
A large, open-label, phase III study (LIBERTY AD SOLO-
MAINTAIN, NCT01949311) is currently investigating the 
extended efficacy and safety of dupilumab in about 2000 
adults who had participated in previous studies. Its results are 
expected in December 2018. The main endpoints will include 
the proportion of patients with IGA=0-1, EASI-75, and low 
disease activity at each visit, as well as any adverse effects 
detected up to 164 weeks [60]. 
A study (NCT03389893) to determine the effect of a 
6-week course of dupilumab on the host-microbe interface 
(cutaneous microbial community structure, skin barrier 
biology, and circulating T-cell profiles) in chronic moderate-
to-severe AD patients was started in 2018.
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Dupilumab for Asthma
Dupilumab has been assessed in clinical trials in patients 
with moderate-to-severe persistent uncontrolled asthma for the 
last 10 years. Phase I studies (NCT01537653, NCT01537640, 
NCT01484600, NCT01015027) were concluded in 2012, 
but data are not yet available. Data from the phase II and 
III studies are now available and show that dupilumab is 
efficient in that it can significantly improve lung function 
(increasing FEV1), reduce exacerbations, and reduce the use 
of maintenance corticosteroids, in this population of patients 
with limited therapeutic choices (Table 2). The Phase III trial 
completed in 2017 was the first study with a biologic to show 
benefits in patients with severe corticosteroid-dependent 
asthma, regardless of blood eosinophil level or any other type 
2 biomarkers at baseline.
Phase II Studies
Data from the first phase II study (NCT01312961) 
were published in 2013 (Table 2) [61]. The study was a 12-
week, randomized, placebo-controlled, parallel-group trial 
that recruited 104 adult patients with moderate-to-severe 
eosinophilic asthma not adequately controlled by inhaled 
corticosteroids (ICSs) and a long-acting ß2 agonist (LABA). 
Participants had been diagnosed with asthma for at least 12 
months and had a high eosinophil count in sputum (≥3%) 
and blood (≥300 cells/µL). They were randomly assigned to 
receive once-weekly subcutaneous injections of dupilumab 
300 mg or placebo. During the trial, patients suspended their 
ICS treatment at week 4 and LABA treatment from weeks 6 
to 9, with the main objective of studying the occurrence of 
asthma exacerbation. Of the 52 participants in the dupilumab 
group, only 2 (6%) had an asthma exacerbation, compared 
with 23 (44%) who experienced exacerbations in the placebo 
group (odds ratio, 0.08; 95% CI, 0.02-0.28; P<.001). In the 
dupilumab group, 2% of patients required reliever medication 
and experienced a reduction in morning peak expiratory flow, 
compared with 19% in the placebo group. Forced expiratory 
volume in 1 second (FEV1) improved by more than 200 mL 
in patients treated with dupilumab compared with placebo, 
and this effect continued even after treatment discontinuation. 
Other parameters that also improved in the dupilumab group 
included morning asthma symptom score, ACQ-5 score, use of 
albuterol, and nocturnal awakenings. The biomarkers FeNO, 
eotaxin-3, serum IgE, and TARC decreased with dupilumab, 
consistent with the known molecular mechanism of dupilumab.
The second pivotal phase II study (NCT01854047) 
included a similar but much larger group (N=776) of patients 
diagnosed with moderate-to-severe uncontrolled asthma 
for >12 months who had received ICSs at medium-to-high 
doses and a LABA twice daily (Table 2) [62]. The patients 
were distributed in 5 groups, receiving 200 mg or 300 mg 
of dupilumab every 2 or 4 weeks or placebo. The study met 
the primary endpoint, change in FEV1 from baseline, which 
increased significantly (except for the dose of 200 mg every 
4 weeks) and ranged from 0.35 to 0.43 L (at 12 weeks) and 
from 0.17 to 0.26 L when compared with placebo. Additionally, 
treatment with dupilumab administered every 2 weeks was 
associated with a reduced (70%-70.5%) risk of the annualized 
severe exacerbation event rates, significant improvements in 
ACQ-5 and AQLQ scores at week 24 when compared with 
placebo, and significant decreases in FeNO. In general, this 
study proved that dupilumab increased lung function and 
reduced severe exacerbations in patients with uncontrolled 
persistent asthma, irrespective of baseline eosinophil counts. 
A recent post hoc analysis of the results of this study was 
performed to examine the effect of dupilumab on the 22-item 
Sino-Nasal Outcome Test (SNOT-22) total score in asthma 
patients with comorbid perennial allergic rhinitis. It concluded 
that dupilumab 300 mg every 2 weeks significantly improved 
allergic rhinitis symptoms in patients with uncontrolled 
persistent asthma and comorbid perennial allergic rhinitis [63].
Phase III Studies
The results of two large phase III studies were completed 
in 2017, and their results were recently made available in part. 
The primary endpoints were met in both cases [29,30,32,33]. 
The pivotal  LIBERTY ASTHMA QUEST trial 
(NCT02414854) enrolled 1902 patients (1795 adults and 107 
adolescents) across 413 study sites worldwide. The study 
analyzed treatment with dupilumab in a broad population 
of patients with uncontrolled, persistent asthma. All patients 
continued on a medium or high dose of ICSs and up to 
2 additional controller medicines throughout the study. 
Dupilumab at a dose of 300 mg reduced severe asthma attacks 
by 46% in the overall population, and 60% or 67% in patients 
with ≥150 or ≥300 eosinophils/μL, respectively (P<.001). The extent 
of the patient’s response correlated with allergic or atopic status, as 
reflected by blood eosinophils and other markers. A poorer response 
was observed in patients with ≤150 eosinophils/μL. The results for 
the 200 mg and 300 mg dupilumab dose groups were generally 
comparable for both exacerbations and FEV1 (Table 2). The 
results of prebronchodilator FEV1 at 12 weeks were equally 
encouraging, as the mean improvement with dupilumab was 
130 mL (9%) for the general population and 210 mL (11%) or 
240 mL (18%) in patients with ≥150 or ≥300 eosinophils/μL, 
respectively (P<.001).
T h e  L I B E RT Y A S T H M A V E N T U R E  s t u d y 
(NCT02528214) enrolled 210 patients (103 in the dupilumab 
arm and 107 in the placebo arm) with severe asthma and 
regular use of maintenance oral corticosteroids (OCSs, 
prednisone or prednisolone) in the 6 months prior to enrolment 
(Table 2)[31]. The study showed that dupilumab reduced 
the use of maintenance OCSs by 70% (median reduction of 
100%) compared with 42% in the case of placebo (median 
reduction of 50%) (P<.0001). In analyses of patients with 
baseline eosinophil counts ≥300 cells/μL, the decrease was 
even greater, with OCS use reduced by 80% on average with 
dupilumab compared with 43% for placebo (P=.0001). At 24 
weeks, despite the reduced use of OCSs, patients treated with 
dupilumab had 59% fewer attacks (exacerbations) in the overall 
population (P<.0001) and 71% fewer attacks in patients with 
eosinophil counts ≥300 cells/µL. Also at 24 weeks, dupilumab 
improved lung function compared with placebo by 220 mL 
(15%) in the overall population, as assessed based on FEV1 
(P=.0007) and by 320 mL (25%) in patients with eosinophil 
counts ≥300 cells/µL (P=.0049). In the overall population, 80% 
of patients who received dupilumab reduced their OCS dose by 
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at least half while maintaining overall asthma control compared 
with 50% for patients who received placebo (P<.0001). In 
addition, 69% of patients who received dupilumab reduced 
their OCS dose to less than 5 mg per day while maintaining 
asthma control compared with 33% of patients who received 
placebo (P<.0001). This was the first study with a biologic to 
show a benefit in the population with severe corticosteroid-
dependent asthma, regardless of blood eosinophil levels or any 
other type 2 biomarkers at baseline [31].
Ongoing Studies
Three ongoing studies are analyzing the safety and efficacy 
of dupilumab in the treatment of moderate-to-severe asthma. 
LIBERTY ASTHMA EXPEDITION (NCT02573233) is a 
placebo-controlled study designed to evaluate the effect of 
dupilumab on airway inflammation in patients with persistent 
asthma. Its main outcomes are the change from baseline in 
inflammatory cell count per square millimeter in the bronchial 
submucosa and change from baseline in the mucin-stained 
area of the bronchial submucosa per square millimeter, over 
a period of treatment of 12 weeks. Its results are expected 
in 2018 [64].
LIBERTY ASTHMA TRAVERSE (NCT02134028) is an 
open-label extension trial with an enrolment of 2206 adolescent 
and adult patients who completed the treatment period in a 
previous dupilumab asthma clinical study. Dupilumab is being 
administered every 2 weeks for a maximum of 60 or 108 weeks 
depending on the enrollment date, and the primary endpoint 
is the evaluation of any adverse events. The study is expected 
to be completed in October 2019 [65].
The third ongoing study, VOYAGE (NCT02948959), is 
specifically evaluating dupilumab every 2 weeks (vs placebo) 
in children aged 6 to <12 years with a diagnosis of persistent 
asthma for ≥12 months. The treatment period will be 52 weeks, 
and the main endpoint will be the annualized rate of severe 
exacerbation events during this treatment period. The results 
are expected by January 2021 [66].
Dupilumab for Chronic Rhinosinusitis 
With Nasal Polyposis
Chronic rhinosinusitis with nasal polyposis is characterized 
by type 2 inflammation with elevated levels of IL-5, IL-13, 
and eosinophils in the polyps [3]. Driven by the success of 
dupilumab in the treatment of other TH2-mediated diseases, 
a phase II study (NCT01920893) was carried out to evaluate 
the efficacy of dupilumab in the treatment of bilateral nasal 
polyposis and chronic symptoms of sinusitis [67]. This 
randomized, double-blind, placebo-controlled study assessed 
the endoscopic nasal polyp score (NPS) and symptoms of 
sinusitis after a 16-week treatment with dupilumab. The 
population analyzed consisted of 60 adults with chronic 
sinusitis and nasal polyposis refractory to intranasal 
corticosteroids. The results, published in 2016, revealed that 
dupilumab added to mometasone furoate nasal spray reduced 
the endoscopic nasal polyp burden after 16 weeks when 
compared with mometasone alone [68]. In addition, significant 
improvements with dupilumab were observed for the 22-item 
SinoNasal Outcome Test and for the sense of smell, assessed 
using the University of Pennsylvania Smell Identification Test. 
Furthermore, a longitudinal analysis of plasma CCL26, an 
eosinophil chemoattractant that is characteristically increased 
in rhinosinusitis with nasal polyposis, showed a decrease in 
levels after treatment with dupilumab.
Two phase III clinical studies, both due to be completed 
in 2018, evaluate the efficacy of dupilumab in reducing the 
severity of nasal congestion/obstruction and endoscopic NPS 
in adult patients also treated with intranasal corticosteroids 
for 24 weeks (SINUS-24, NCT02912468, estimated N=240) 
or a 52-week treatment period (SINUS-52, NCT02898454, 
estimated N=360) [69,70].
Dupilumab for Eosinophilic  
Esophagitis 
EoE has only been considered a chronic allergic/immune 
condition in recent decades [71]. Patients with EoE present 
inflammation of the esophagus, with abundant eosinophilia. 
Although many aspects of the pathophysiology of this disease 
remain unclear, the excess of eosinophils in the esophageal 
epithelium points to the recruiting action of TH2 cytokines 
IL-4, IL-5, and IL-13 [71,72]. For this reason, dupilumab was 
considered a possible therapy for this disease.
A phase II, randomized, double-blind, placebo-controlled 
clinical trial (NCT02379052) was carried out with 47 
participants to assess the clinical efficacy of dupilumab for 
relieving symptoms in adult patients with active, moderate-
to-severe EoE [73]. The study was completed in July 2017 
and the preliminary results were presented at the World 
Congress of Gastroenterology the same year [38]. The primary 
endpoint of the study was the change from baseline to week 
10 in the Straumann Dysphagia Instrument (SDI) score, a 
patient-reported measure of swallowing difficulty on a 0-9 
point scale, with 9 indicating more severe symptoms. A total 
of 47 patients were randomized to 2 treatment groups in this 
12-week treatment study, and both groups had a mean baseline 
SDI score of 6.4. Patients received either dupilumab 300 mg 
weekly following a 600-mg loading dose or placebo. At week 
10, patients who received dupilumab reported a significant 
improvement in the ability to swallow with a 3-point reduction 
in their SDI score (45% improvement) compared with 
1.3 points (19% improvement) for those patients who received 
placebo (P=.0304) [38]. Notably, the mean percent change in 
overall peak intraepithelial eosinophil count from baseline to 
12 weeks was significantly reduced by 93% from baseline in 
patients who received dupilumab weekly compared with an 
increase of 14% in those who received placebo (P<.0001) 
[38], thus highlighting the action of dupilumab against the 
root mechanism of the disease.
In conclusion, the study revealed that dupilumab 
significantly improved dysphagia, esophageal eosinophil 
counts, endoscopic features, histology, and esophageal 
distensibility in adults with active EoE compared with 
placebo [38].
Dupilumab recently received orphan drug status for the 
treatment of EoE from the Orphan Drug Designation program 
of the FDA [38].
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Safety and Tolerability of Dupilumab
In all AD trials, the incidence of adverse events was 
similar in the dupilumab groups and the placebo groups. 
Serious adverse events and adverse events leading to treatment 
discontinuation were uncommon [14,54,56,59,74]. However, 
in long-term studies, the rates of conjunctivitis, injection site 
reactions, and local herpes simplex infections were higher 
in the dupilumab groups than in the placebo groups [56,57]. 
Two recent meta-analyses of randomized clinical trials of 
dupilumab for the treatment of AD showed that treated 
patients presented a lower risk of skin infection (risk ratio, 
0.54; 95%CI, 0.42-0.69) [75] and eczema herpeticum [76]. 
Furthermore, the risk decreased for exacerbation of AD (risk 
ratio, 0.44; 95%CI, 0.34-0.59) [75]. However, the risks were 
higher in the groups treated with dupilumab for injection 
site reactions (risk ratio, 2.24; 95%CI, 1.68-2.99), headache 
(risk ratio, 1.47; 95%CI, 1.05-2.06), and conjunctivitis (risk 
ratio, 2.64; 95%CI, 1.79-3.89) than in patients treated with 
placebo [75]. Nasopharyngitis, urinary tract infection, upper 
respiratory tract infection, and herpes virus infection were 
equally distributed between the dupilumab groups and placebo 
groups [75].
In the SOLO-1 and SOLO-2 studies, as well as in the 
LIBERTY AD CHRONOS study, the longest-running study (1 
year) for which there are available data, the rates of conjunctivitis 
(allergic or unspecified) were higher in the dupilumab groups 
than in the placebo groups [54,56,57]. It has been speculated that 
this increment in the frequency of conjunctivitis could limit the 
use of dupilumab in the treatment of allergic diseases, especially 
in children [77]. However, in the SOLO trials, more than 90% 
of the adverse events of conjunctivitis were mild or moderate in 
severity, and more than 75% resolved or were resolving during 
study treatment (only 1 of 920 patients treated with dupilumab 
had to discontinue because of conjunctivitis). Importantly, 
other dupilumab trials involving patients with asthma or 
nasal polyposis did not show a higher rate of conjunctivitis 
than placebo, suggesting an AD-specific mechanism [74]. 
Furthermore, the incidence of atopic keratoconjunctivitis 
was less than 0.5% across all groups and was no higher in 
the dupilumab group than in the placebo group [74]. The 
causes of the increased incidence of conjunctivitis in trials 
investigating dupilumab for the treatment of AD remain 
unknown, and further research will be required to evaluate the 
overall effect of the drug in AD therapy. Although the effect 
of IL-13 on regulation of conjunctival goblet cell density is 
not completely understood, the fact that IL-13–deficient mice 
have a significantly lower number of filled conjunctival goblet 
cells than wild-type mice suggested a potential role of IL-13 in 
regulating conjunctival goblet cells and, therefore, the quality 
of tears. This could compromise the protective function of tears, 
thereby contributing to ocular surface damage and inducing 
dry eye syndrome in some patients. In fact, the use of artificial 
tears is recommended in patients receiving dupilumab [78,79]. 
The presence of inflammation of the anterior conjunctiva and 
hyperemia of the limbus was recently reported in 25%-50% 
of AD patients treated with dupilumab. The condition was 
successfully treated with fluorometholone 0.1% eye drops or 
tacrolimus 0.03% eye ointment [80].
In the LIBERTY ASTHMA QUEST study, a long-term 
analysis, the overall rates of adverse events, deaths, infections, 
conjunctivitis, herpes, and discontinuations were comparable 
between the dupilumab and the placebo groups. Injection site 
reactions were more common in the dupilumab groups (17% 
vs 8%) [29,32,33]. Transient increases in serum eosinophil 
levels have been reported in some asthmatic patients at the 
beginning of treatment with dupilumab.
In all the dupilumab clinical trials, including those with 
treatment periods of 52 weeks, only 10% of patients developed 
antidrug antibodies. In most cases, the antibody titer was low 
and the effect transitory (<1% persistent) [24]. Given the low 
incidence of immunogenicity, its relevance for efficacy or 
safety could not be determined. The LIBERTY AD SOLO-
MAINTAIN clinical trial (NCT01949311), which comprises 
164 weeks of treatment, will analyze the long-term safety and 
immunogenicity of dupilumab [60].
Dose adjustment is not recommended in elderly patients 
(≥65 years) or as a function of body weight and is not 
needed in patients with mild or moderate kidney impairment. 
The efficacy and safety profile of dupilumab has not been 
established in patients with liver impairment or in patients 
aged ≤18 years [23].
Taken together, the clinical data suggest that dupilumab is 
generally well tolerated and that the common adverse events 
are mild and manageable. Long-term data on AD and asthma 
reported from clinical trials support the view that dupilumab is 
very safe, although data from extension studies and in children 
(both for AD and asthma) will definitely clarify this issue.
Dupilumab: Implications for Clinical 
Practice
Dupilumab is the first biologic that effectively addresses 
the pathophysiology of allergic syndromes, the TH2-driven 
inflammatory pathway. The FDA approval of dupilumab has 
paved the way for biologic therapy to be used as treatment 
of moderate-to-severe AD. Compared with other biologics 
(eg, nemolizumab, lebrikizumab, tralokinumab), dupilumab 
is currently the only biologic with robust evidence of efficacy 
in AD [26]. 
Treatment with dupilumab is also potentially useful 
in patients with moderate-to-severe asthma who are not 
adequately controlled with ICS+LABA [30,81], since it 
enables reduction or suspension of systemic corticosteroids, 
decreases exacerbations, and improves lung function. 
Furthermore, dupilumab has proven to be effective in 
asthmatic patients independent of eosinophil levels in blood 
[62], while the biologics that block the IL-5/IL-5Rα axis 
(mepolizumab, reslizumab, and benralizumab) are restricted 
to uncontrolled severe asthma patients with >300 eosinophils/
μL (mepolizumab, benralizumab) or >400 eosinophils/μL 
(reslizumab) [82]. 
Another major advantage of dupilumab could be that it 
effectively addresses AD/asthma and their main comorbidities 
(eg, chronic sinusitis, nasal polyposis). Dupilumab could 
therefore have a major therapeutic impact on several allergic 
diseases simultaneously. 
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In a decade of intense clinical research, dupilumab has 
proven an efficacious and safe tool in the management of AD 
and asthma in its more severe presentations and for which 
there were no therapeutic alternatives. As data from new 
studies become available, it is likely that dupilumab will show 
its potential in a wider range of allergic diseases and lead the 
way to the targeted modulation of the immune system for 
therapeutic purposes.
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